

FAX

01/10/98 10:59 Pg: 1



Formerly ASTRA MERCK

FROM Alan P. Baker, Ph. D. Director	PHONE 610-695-1548	DATE October 1, 1998
DEPARTMENT Business Development E-mail: alan.baker@astramerck.com		FAX NO. 610-644-0486
TO  L. J. McDermott		FAX NO. 011 33 145 00 2969
SUBJECT ADD 234037		PAGES 1


Dear Larry,

As I indicated in my telefax dated September 24, Astra has no interest in ADD 234037. It was decided that we would concentrate on the development of Remacemide and not expand our effort beyond that with respect to epilepsy. Remacemide is a NMDA antagonist that Astra acquired from their acquisition of Fisons' R&D effort; it is in Phase III clinical trials.

Regarding my visit to Paris, it looks as if next week is out. I am now trying for the following week (10/12-16). Keep you posted.

Regards,

Sincerely yours,

  
Alan P. Baker, Ph. D.

*ALAN:*  
 Thanks for the fax.  
 I look forward to hearing from you as to when you think you'll be in PARIS next.

*J. J. [Signature]*

*10/1/98*

MAILING ADDRESS:  
Astra Pharmaceuticals, L.P.  
725 Chesterbrook Blvd.  
Wayne, PA 19087-3677

harris10-198.doc

TOTAL F.01